Media and Analysts Invited: Company Will Announce Recent Drive into Profitability and Expanding U.S. Marketing Channels for Its Over-the-Counter Pain Reliever, Cobroxin
Product to be Marketed in 14,000+ CVS Pharmacies and Walgreens Nationwide
Nutra Pharma, a Florida-based biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases will host a media & analyst conference.
NASDAQ MarketSite, 4 Times Square, New York, NY
Tuesday, April 27th – 12:15PM EDT
RSVP required for building security: 212-699-0999 or email email@example.com
Click here to schedule the LIVE WEBCAST LINK into your Outlook calendar. Select "open" then "save and close"
when prompted. Click here to watch the event 4/27,12:15pm
CEO Rik Deitsch will discuss the corporate initiatives for the marketing and distribution of Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin.
Deitsch will also speak on new proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN) and Human Immunodeficiency Virus (HIV).
Samples of Cobroxin will be available.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Hosting a media and analyst conference at the NASDAQ MarketSite should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.